Thus, CLEC2 is a novel pattern recognition receptor for SARS‐CoV‐2, and CLEC2.Fc may become a promising therapeutic agent to protect COVID‐19 patients from thromboinflammation and reduce PASC in the future. The gene discussed is CLEC1B; the disease is COVID-19.